Pomalidomide for multiple myeloma

References

• Kyle RA, Rajkumar SV. Epidemiology of the plasma-cell disorders. Best Pract Res Clin Haematol 2007;20(4):637-64
   PubMed Web of Science ®Google Scholar
• Multiple myeloma. Cancer of the bone marrow. International Myeloma Foundation; (ed 2008/2009)
   Google Scholar
• Kumar S, Rajkumar SV, Dispenzieri A. Improved survival in multiple myeloma and the impact of novel therapies. Blood 2008;111(5):2516-20
   PubMed Web of Science ®Google Scholar
• Kumar SK, Lee JH, Lahuerta JJ, et al. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study. Leukemia 2012;26(1):149-57
   PubMed Web of Science ®Google Scholar
• Chanan-Khan AA, Swaika A, Paulus A, et al. Pomalidomide: the new immunomodulatory agent for the treatment of multiple myeloma. Blood Cancer J 2013;3:e143
   PubMed Web of Science ®Google Scholar
• Mitsiades N, Mitsiades CS, Poulaki V, et al. Biologic sequelae of nuclear factor-kappaB blockade in multiple myeloma: therapeutic applications. Blood 2002;99(11):4079-86
   PubMed Web of Science ®Google Scholar
• Zhu YX, Kortuem KM, Stewart AK. Molecular mechanism of action of immune-modulatory drugs thalidomide, lenalidomide and pomalidomide in multiple myeloma. Leuk Lymph 2013;54(4):683-7
   PubMed Web of Science ®Google Scholar
• D’Amato RJ, Loughnan MS, Flynn E, Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 1994;91(9):4082-5
   PubMed Web of Science ®Google Scholar
• Kumar S, Greipp PR, Haug JL, et al. Correlation of bone marrow angiogenesis and response to thalidomide dexamethasone in multiple myeloma. J Clin Oncol (Meeting Abstracts) 2006;24(Suppl 18):7621
   Google Scholar
• Anderson G, Gries M, Kurihara N, et al. Thalidomide derivative CC-4047 inhibits osteoclast formation by down-regulation of PU.1. Blood 2006;107(8):3098-105
   PubMed Web of Science ®Google Scholar
• Haslett PA, Corral LG, Albert M, Kaplan G. Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset. J Exp Med 1998;187(11):1885-92
   PubMed Web of Science ®Google Scholar
• Davies FE, Raje N, Hideshima T, et al. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood 2001;98(1):210-16
   PubMed Web of Science ®Google Scholar
• Galustian C, Meyer B, Labarthe MC, et al. The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells. Cancer Immunol Immunother 2009;58(7):1033-45
   PubMed Web of Science ®Google Scholar
• Ferguson GD, Jensen-Pergakes K, Wilkey C, et al. Immunomodulatory drug CC-4047 is a cell-type and stimulus-selective transcriptional inhibitor of cyclooxygenase 2. J Clin Immunol 2007;27(2):210-20
   PubMed Web of Science ®Google Scholar
• Lopez-Girona A, Mendy D, Ito T, et al. Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide. Leukemia 2012;26(11):2326-35
   PubMed Web of Science ®Google Scholar
• Zhu YX, Braggio E, Shi CX, et al. Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide. Blood 2011;118(18):4771-9
   PubMed Web of Science ®Google Scholar
• Broyl A, Kuiper R, van Duin M, et al. High cereblon expression is associated with better survival in patients with newly diagnosed multiple myeloma treated with thalidomide maintenance. Blood 2013;121(4):624-7
   PubMed Web of Science ®Google Scholar
• Huang SY, Lin CW, Lin HH, et al. Expression of cereblon protein assessed by immunohistochemicalstaining in myeloma cells is associated with superior response of thalidomide- and lenalidomide-based treatment, but not bortezomib-based treatment, in patients with multiple myeloma. Ann Hematol 2014;93(8):1371-80
   PubMed Web of Science ®Google Scholar
• Heintel D, Rocci A, Ludwig H, et al. High expression of cereblon (CRBN) is associated with improved clinical response in patients with multiple myeloma treated with lenalidomide and dexamethasone. Br J Haematol 2013;161(5):695-700
   PubMed Web of Science ®Google Scholar
• Schuster SR, Kortuem KM, Zhu YX. Cereblon expression predicts response, progression free and overall survival after pomalidomide and dexamethasone therapy in multiple myeloma. ASH Annual Meeting Abstracts 2012;120(21):194
   Google Scholar
• Lu G, Middleton RE, Sun H, et al. The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins. Science 2014;343(6168):305-9
   PubMed Web of Science ®Google Scholar
• Lode L, Amiot M, Maiga S, et al. Cereblon expression in multiple myeloma: not ready for prime time. Br J Haematol 2013;163(2):282-4
   PubMedGoogle Scholar
• European Medicines Agency. Imnovid (pomalidomide). Summary of product characteristics. Available from: www.ema.europa.eu
   Google Scholar
• Kasserra C, Assaf M, Hoffmann M, et al. Pomalidomide: Evaluation of cytochrome P450 and transporter-mediated drug-drug interaction potential in vitro and in healthy subjects. J Clin Pharmacol 2014. [Epub ahead of print]
   PubMedGoogle Scholar
• Lacy MQ, McCurdy AR. Pomalidomide. Blood 2013;122(14):2305-9
   PubMed Web of Science ®Google Scholar
• Schey SA, Fields P, Bartlett JB, et al. Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma. J Clin Oncol 2004;22(16):3269-76
   PubMed Web of Science ®Google Scholar
• Streetly MJ, Gyertson K, Daniel Y, et al. Alternate day pomalidomide retains anti-myeloma effect with reduced adverse events and evidence of in vivo immunomodulation. Br J Haematol 2008;141(1):41-51
   PubMed Web of Science ®Google Scholar
• Richardson PG, Siegel D, Baz R, et al. Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomib. Blood 2013;121(11):1961-7
   PubMed Web of Science ®Google Scholar
• Lacy MQ, Hayman SR, Gertz MA, et al. Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma. J Clin Oncol 2009;27(30):5008-14
   PubMed Web of Science ®Google Scholar
• Lacy M, Kumar S, LaPlant B. Pomalidomide plus low-dose dexamethasone (pom/dex) in relapsed myeloma: long term follow up and factors predicting outcome in 345 patients. ASH Annual Meeting Abstracts 2012;120(21):201
   Google Scholar
• Lacy MQ, Hayman SR, Gertz MA, et al. Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM). Leukemia 2010;24(11):1934-9
   PubMed Web of Science ®Google Scholar
• Lacy MQ, Allred JB, Gertz MA, et al. Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory disease. Blood 2011;118(11):2970-5
   PubMed Web of Science ®Google Scholar
• Richardson PG, Siegel DS, Vij R, et al. Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized Phase II study. Blood 2014;123(12):1826-32
   PubMed Web of Science ®Google Scholar
• Leleu X, Attal M, Arnulf B, et al. Pomalidomide plus low-dose dexamethasone is active and well tolerated in bortezomib and lenalidomide-refractory multiple myeloma: intergroupe Francophone du Myelome 2009-02. Blood 2013;121(11):1968-75
   PubMed Web of Science ®Google Scholar
• San Miguel J, Weisel K, Moreau P, et al. Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, Phase III trial. Lancet Oncol 2013;14(11):1055-66
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Weisel K, Song KW, et al. Final analysis, cytogenetics, long-term treatment, and long-term survival in MM-003, A Phase 3 Study Comparing Pomalidomide + Low-Dose Dexamethasone (POM + LoDEX) vs High-Dose Dexamethasone (HiDEX) in Relapsed/Refractory Multiple Myeloma (RRMM). Blood (ASH Annual Meeting Abstracts) 2013;122(Suppl 1):abstract 408
   Google Scholar
• San Miguel J, Weisel KC, Song KW, et al. Patient Outcomes by Prior Therapies and Depth of Response : Analysis of MM-003, a Phase 3 Study Comparing Pomalidomide + Low-Dose Dexamethasone vs High-Dose Dexamethasone in Relapsed/Refractory Multiple Myeloma Blood. ASH Annual Meeting Abstract 2013;122(Suppl 1):abstract 686
   Google Scholar
• Weisel KC, Dimopoulos MA, Moreau P. Pomalidomide plus low-dose dexamethasone (POM 1 LoDEX) versus high-dose dexamethasone (HiDEX) in relapsed/refractory multiple myeloma (RRMM): MM-003 analysis of patients (pts) with moderate renal impairment (RI). ASCO Meeting Abstracts 2013;31(Suppl 15):8527
   Google Scholar
• Goldschmidt H, Dimopoulos MA, Weisel KC. Pomalidomide plus low-dose dexamethasone (POM 1 LoDEX) versus high-dose dexamethasone (HiDEX) in relapsed/refractory multiple myeloma (RRMM): Impact of cytogenetics in MM-003. ASCO Meeting Abstracts 2013;31(Suppl 15):8528
   Google Scholar
• Evaluation of Safety of Pomalidomide in Combination With Dexamethasone (Low Dose) in Patients With Refractory or Relapsed and Refractory Multiple Myeloma (STRATUS). Available from: www.clinicaltrials.gov/show/NCT01712789
   Google Scholar
• Safety and Efficacy of Pomalidomide, Bortezomib and Low-dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma (OPTIMISMM). Available from: http://clinicaltrials.gov/show/NCT01734928
   Google Scholar
• Richardson P, Hofmeister CC, Siegel D. MM-005: A phase I trial of pomalidomide, bortezomib, and low-dose dexamethasone (PVD) in relapsed and/or refractory multiple myeloma (RRMM). ASCO Meeting Abstracts 2013;31(Suppl 15):8584
   Google Scholar
• Shah JJ, Stadtmauer EA, Abonour R. A multi-center phase I/II trial of carfilzomib and pomalidomide with dexamethasone (Car-Pom-d) in patients with relapsed/refractory multiple myeloma. ASH Annual Meeting Abstracts 2012;120(21):74
   Google Scholar
• Stadtmauer E, Shah J, Abonour R, et al. Carfilzomib, pomalidomide and dexamethasone (CPomd) for relapsed/refractory multiple myeloma (RRMM): a phase I/II trial. Clin Lymphoma Myeloma Leuk (IMW Annu Meet Abstr) 2013;13(Suppl 1):abstract P-250
   Google Scholar
• Shah JJ, Edward A, Stadtmauer EA, et al. A Multi-Center Phase I/II Trial of Carfilzomib and Pomalidomide With Dexamethasone (CAR-POM-D) in Patients with Relapsed/Refractory Multiple Myeloma. Blood (ASH Annual Meeting Abstract) 2013;122(Suppl):abstract 690
   Google Scholar
• Larocca A, Montefusco V, Bringhen S, et al. Pomalidomide, cyclophosphamide, and prednisone for relapsed/refractory multiple myeloma: a multicenter Phase I/2 open-label study. Blood 2013;122(16):2799-806
   PubMed Web of Science ®Google Scholar
• Berenson JR, Hilger JD, Klein LM. A Phase I/2 study of pomalidomide, dexamethasone and pegylated liposomal doxorubicin for patients with relapsed/refractory multiple myeloma. ASH Annual Meeting Abstracts 2012;120(21):2979
   Google Scholar
• Mark TM, Boyer A, Rossi AC. ClaPD (clarithromycin, pomalidomide, dexamethasone) therapy in relapsed or refractory multiple myeloma. ASH Annual Meeting Abstracts 2012;120(21):77
   Google Scholar
• Dimopoulos MA, Leleu X, Palumbo A, et al. Expert panel consensus statement on the optimal use of pomalidomide in relapsed and refractory multiple myeloma. Leukemia 2014;28(8):1573-9
   PubMed Web of Science ®Google Scholar
• Siegel DS, Richardson PG, Hofmeister C, et al. Adverse event management of pomalidomide + low-dose dexamethasone in relapsed and refractory multiple myeloma. Clin Lymphoma Myeloma Leuk (IMW Annu Meet Abstr) 2013;13(Suppl 1):abstract P-399
   Google Scholar
• Geyer HL, Viggiano RW, Lacy MQ, et al. Acute lung toxicity related to pomalidomide. Chest 2011;140(2):529-33
   PubMed Web of Science ®Google Scholar
• U.S. Food and Drug Administration. POMALYST (pomalidomide). Approved Drugs. Available from: www.fda.gov/Drugs [Last accessed on December 2013]
   Google Scholar
• Pomalyst. Available from: www.pomalyst.com/wp-content/uploads/2013/08/prescribing_information.pdf
   Google Scholar
• Matous J, Siegel DS, Duong HK, et al. MM-008 : A Phase 1 Trial Evaluating Pharmacokinetics and Tolerability Of Pomalidomide + Low-Dose Dexamethasone In Patients With Relapsed/Refractory Multiple Myeloma and Renal Impairment. Blood (ASH Annual Meeting Abstracts) 2013;122(21):5393
   Google Scholar
• Leleu X, Karlin L, Macro M, et al. Pomalidomide plus low-dose dexamethasone in relapsed or refractory multiple myeloma (RRMM) with deletion (del)17p and/or translocation t(4;14). Blood (ASH Annual Meeting Abstracts) 2013;122:abstract 689
   Google Scholar
• Pomalidomide and Dexamethasone Effects in Multiple Myeloma Patients With Del 17p or t (4;14) (IFM2010-02). Available from: http://clinicaltrials.gov/show/NCT01745640
   Google Scholar
• Short KD, Rajkumar SV, Larson D, et al. Incidence of extramedullary disease in patients with multiple myeloma in the era of novel therapy, and the activity of pomalidomide on extramedullary myeloma. Leukemia 2011;25(6):906-8
   PubMed Web of Science ®Google Scholar
• Jagannath S, Hofmeister CC, Baz RC, et al. Pomalidomide (POM) with or without low-dose dexamethasone (LoDEX) in patients (Pts) with relapsed and refractory multiple myeloma (RRMM): MM-002 phase II age subgroup analysis. J Clin Oncol (ASCO Annu Meet Proc) 2013;31(Suppl):abstract 8532
   Google Scholar
• Jagannath S, Hofmeister C, Baz R, et al. The efficacy and safety of pomalidomide with or without low-dose dexamethasone is not impacted by age in patients with advanced relapsed and refractory multiple myeloma: MM-002 subgroup analysis. Haematologica (EHA Annu Meet Abstr) 2013;98(Suppl 1):abstract P778
   Google Scholar
• Mesa RA, Pardanani AD, Hussein K, et al. Phase1/-2 study of Pomalidomide in myelofibrosis. Am J Hematol 2010;85(2):129-30
   PubMed Web of Science ®Google Scholar
• Tefferi A, Verstovsek S, Barosi G, et al. Pomalidomide is active in the treatment of anemia associated with myelofibrosis. J Clin Oncol 2009;27(27):4563-9
   PubMed Web of Science ®Google Scholar
• Begna KH, Mesa RA, Pardanani A, et al. A phase-2 trial of low-dose pomalidomide in myelofibrosis. Leukemia 2011;25(2):301-4
   PubMed Web of Science ®Google Scholar
• Moutouh-de Parseval LA, Verhelle D, Glezer E, et al. Pomalidomide and lenalidomide regulate erythropoiesis and fetal hemoglobin production in human CD34+ cells. J Clin Invest 2008;118(1):248-58
   PubMedGoogle Scholar
• San Miguel J, Weisel KC, Moreau P. Quality of life improvements for pomalidomide + low-dose dexamethasone (POM + LoDEX) in relapsed and refractory multiple myeloma. Haematologica 2013;98(Suppl 1):abstract 430
   Google Scholar
• Study of Pomalidomide, Cyclophosphamide, Dexamethasone in Relapsed/Refractory Multiple Myeloma. http://clinicaltrials.gov/show/NCT02176213
   Google Scholar
• Richardson PG, Hofmeister CC, Siegel DS, et al. MM-005 : A Phase 1 Trial of Pomalidomide, Bortezomib, and Low-Dose Dexamethasone (PVD) in Relapsed and/or Refractory Multiple Myeloma. Blood (ASH Annual Meeting Abstract) 2013;122(Suppl):abstract 1969
   Google Scholar
• Berenson JR, Hilger JD, Klein L, et al. Pomalidomide, dexamethasone and pegylated liposomal doxorubicin for patients with relapsed/refractory multiple myeloma: results from a phase 1/2 trial. Blood (ASH Annual Meeting Abstract) 2013;122(Suppl):abstract 3218
   Google Scholar
• Mark TM, Boyer A, Rossi AC, et al. Clapd (Clarithromycin, Pomalidomide, Dexamethasone) therapy in relapsed or refractory multiple myeloma. Blood (ASH Annual Meeting Abstract) 2013;122(Suppl):abstract 1955
   Google Scholar
• von Lilienfeld-Toal M, Hahn-Ast C, Furkert K, et al. A systematic review of phase II trials of thalidomide/dexamethasone combination therapy in patients with relapsed or refractory multiple myeloma. Eur J Haematol 2008;81(4):247-52
   PubMed Web of Science ®Google Scholar
• Mariz JM, Esteves GV. Review of therapy for relapsed/refractory multiple myeloma: focus on lenalidomide. Curr Opin Oncol 2012;24(Suppl 2):S3-11
   Google Scholar
• Mateos MV. Management of treatment-related adverse events in patients with multiple myeloma. Cancer Treat Rev 2010;36(Suppl 2):S24-32
   Google Scholar
• FDA. Available from: www.accessdata.fda.gov/
   Google Scholar